264 related articles for article (PubMed ID: 33993343)
1. Effectiveness of palonosetron versus granisetron in preventing chemotherapy-induced nausea and vomiting: a systematic review and meta-analysis.
Hsu YC; Chen CY; Tam KW; Hsu CY
Eur J Clin Pharmacol; 2021 Nov; 77(11):1597-1609. PubMed ID: 33993343
[TBL] [Abstract][Full Text] [Related]
2. Antiemetics for adults for prevention of nausea and vomiting caused by moderately or highly emetogenic chemotherapy: a network meta-analysis.
Piechotta V; Adams A; Haque M; Scheckel B; Kreuzberger N; Monsef I; Jordan K; Kuhr K; Skoetz N
Cochrane Database Syst Rev; 2021 Nov; 11(11):CD012775. PubMed ID: 34784425
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of clinical outcomes and efficacy of palonosetron and granisetron in combination with dexamethasone in Egyptian patients receiving highly emetogenic chemotherapy.
A Mahrous M; A El-Azab G; A Tawfik H
Cancer Chemother Pharmacol; 2021 Jul; 88(1):121-129. PubMed ID: 33835230
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of triplet regimen antiemetic therapy for chemotherapy-induced nausea and vomiting (CINV) in bone and soft tissue sarcoma patients receiving highly emetogenic chemotherapy, and an efficacy comparison of single-shot palonosetron and consecutive-day granisetron for CINV in a randomized, single-blinded crossover study.
Kimura H; Yamamoto N; Shirai T; Nishida H; Hayashi K; Tanzawa Y; Takeuchi A; Igarashi K; Inatani H; Shimozaki S; Kato T; Aoki Y; Higuchi T; Tsuchiya H
Cancer Med; 2015 Mar; 4(3):333-41. PubMed ID: 25533447
[TBL] [Abstract][Full Text] [Related]
5. Serotonin receptor antagonists for highly emetogenic chemotherapy in adults.
Billio A; Morello E; Clarke MJ
Cochrane Database Syst Rev; 2010 Jan; (1):CD006272. PubMed ID: 20091591
[TBL] [Abstract][Full Text] [Related]
6. Transdermal granisetron versus palonosetron for prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: a multicenter, randomized, open-label, cross-over, active-controlled, and phase IV study.
Seol YM; Kim HJ; Choi YJ; Lee EM; Kim YS; Oh SY; Koh SJ; Baek JH; Lee WS; Joo YD; Lee HG; Yun EY; Chung JS
Support Care Cancer; 2016 Feb; 24(2):945-952. PubMed ID: 26265119
[TBL] [Abstract][Full Text] [Related]
7. Palonosetron for prevention of delayed chemotherapy-induced nausea and vomiting in pediatric patients: a meta-analysis.
Yamaguchi A; Saito Y; Takekuma Y; Sugawara M
Support Care Cancer; 2023 Dec; 32(1):58. PubMed ID: 38145979
[TBL] [Abstract][Full Text] [Related]
8. Comparison of two different intravenous serotonin antagonists used for chemotherapy-induced nausea and vomiting prophylaxis in patients treated with moderately emetogenic risk regimens: A retrospective analysis from a large academic medical center.
Gamble M; Carroll E; Wright GC; Glode AE
J Oncol Pharm Pract; 2020 Dec; 26(8):1964-1969. PubMed ID: 32633661
[TBL] [Abstract][Full Text] [Related]
9. Should palonosetron be a preferred 5-HT
Chow R; Warr DG; Navari RM; Tsao M; Popovic M; Chiu L; Milakovic M; Lam H; DeAngelis C
Support Care Cancer; 2018 Aug; 26(8):2519-2549. PubMed ID: 29796708
[TBL] [Abstract][Full Text] [Related]
10. A systematic review and meta-analysis of intravenous palonosetron in the prevention of chemotherapy-induced nausea and vomiting in adults.
Likun Z; Xiang J; Yi B; Xin D; Tao ZL
Oncologist; 2011; 16(2):207-16. PubMed ID: 21282670
[TBL] [Abstract][Full Text] [Related]
11. Comparison of an extended-release formulation of granisetron (APF530) versus palonosetron for the prevention of chemotherapy-induced nausea and vomiting associated with moderately or highly emetogenic chemotherapy: results of a prospective, randomized, double-blind, noninferiority phase 3 trial.
Raftopoulos H; Cooper W; O'Boyle E; Gabrail N; Boccia R; Gralla RJ
Support Care Cancer; 2015 Mar; 23(3):723-32. PubMed ID: 25179689
[TBL] [Abstract][Full Text] [Related]
12. Risk factors associated with chemotherapy-induced nausea and vomiting in the triplet antiemetic regimen including palonosetron or granisetron for cisplatin-based chemotherapy: analysis of a randomized, double-blind controlled trial.
Tsuji D; Suzuki K; Kawasaki Y; Goto K; Matsui R; Seki N; Hashimoto H; Hama T; Yamanaka T; Yamamoto N; Itoh K
Support Care Cancer; 2019 Mar; 27(3):1139-1147. PubMed ID: 30094732
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness of a fixed combination of netupitant and palonosetron (NEPA) relative to aprepitant plus granisetron (APR + GRAN) for prophylaxis of chemotherapy-induced nausea and vomiting (CINV): a trial-based analysis.
Botteman M; Nickel K; Corman S; Turini M; Binder G
Support Care Cancer; 2020 Feb; 28(2):857-866. PubMed ID: 31161436
[TBL] [Abstract][Full Text] [Related]
14. Granisetron in the treatment of chemotherapy-induced nausea and vomiting (CINV) - is there still a role after comparison with palonosetron?
Doggrell SA
Expert Opin Pharmacother; 2017 Jul; 18(10):1019-1026. PubMed ID: 28612633
[TBL] [Abstract][Full Text] [Related]
15. A narrative review of tropisetron and palonosetron for the control of chemotherapy-induced nausea and vomiting.
Yang Y; Zhang L
Chin Clin Oncol; 2020 Apr; 9(2):17. PubMed ID: 31865713
[TBL] [Abstract][Full Text] [Related]
16. Palonosetron plus dexamethasone versus granisetron plus dexamethasone for prevention of nausea and vomiting during chemotherapy: a double-blind, double-dummy, randomised, comparative phase III trial.
Saito M; Aogi K; Sekine I; Yoshizawa H; Yanagita Y; Sakai H; Inoue K; Kitagawa C; Ogura T; Mitsuhashi S
Lancet Oncol; 2009 Feb; 10(2):115-24. PubMed ID: 19135415
[TBL] [Abstract][Full Text] [Related]
17. A double-blind, randomized, multicenter phase 3 study of palonosetron vs granisetron combined with dexamethasone and fosaprepitant to prevent chemotherapy-induced nausea and vomiting in patients with breast cancer receiving anthracycline and cyclophosphamide.
Matsumoto K; Takahashi M; Sato K; Osaki A; Takano T; Naito Y; Matsuura K; Aogi K; Fujiwara K; Tamura K; Baba M; Tokunaga S; Hirano G; Imoto S; Miyazaki C; Yanagihara K; Imamura CK; Chiba Y; Saeki T
Cancer Med; 2020 May; 9(10):3319-3327. PubMed ID: 32168551
[TBL] [Abstract][Full Text] [Related]
18. A review of granisetron, 5-hydroxytryptamine3 receptor antagonists, and other antiemetics.
Hsu ES
Am J Ther; 2010; 17(5):476-86. PubMed ID: 20844345
[TBL] [Abstract][Full Text] [Related]
19. Comparative efficacy and safety of palonosetron with the first 5-HT3 receptor antagonists for the chemotherapy-induced nausea and vomiting: a meta-analysis.
Jin Y; Sun W; Gu D; Yang J; Xu Z; Chen J
Eur J Cancer Care (Engl); 2013 Jan; 22(1):41-50. PubMed ID: 22519361
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of palonosetron (PAL) compared to other serotonin inhibitors (5-HT3R) in preventing chemotherapy-induced nausea and vomiting (CINV) in patients receiving moderately or highly emetogenic (MoHE) treatment: systematic review and meta-analysis.
Botrel TE; Clark OA; Clark L; Paladini L; Faleiros E; Pegoretti B
Support Care Cancer; 2011 Jun; 19(6):823-32. PubMed ID: 20495832
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]